BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting
November 01 2017 - 9:00AM
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical
company focused on developing and commercializing innovative
molecularly targeted and immuno-oncology drugs for the treatment of
cancer, today announced that it will present data on its Bruton’s
Tyrosine Kinase (BTK) inhibitor at the upcoming 59th American
Society of Hematology (ASH) Annual Meeting. ASH will take place
December 9-12, 2017 in Atlanta, GA.
Oral Presentation, Abstract #152
Title: Safety and Activity of the Highly
Specific BTK Inhibitor BGB-3111 in Patients with Indolent and
Aggressive Non Hodgkin’s Lymphoma
Presenter: Constantine Tam, MD
Session: 623. Mantle Cell, Follicular, and
Other Indolent B-Cell Lymphoma – Clinical Studies: Mantle Cell
Lymphoma, New TherapiesDate & Time: 12:15pm
EST, Saturday, December 9, 2017Location: Georgia
World Congress Center, A411-A412
Poster, Abstract #1745
Title: BGB-3111 in Combination with
Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and
Follicular Lymphoma
Presenter: Constantine Tam, MD
Session: 642. CLL: Therapy, excluding
Transplantation: Poster IDate & Time:
5:30pm-7:30pm EST, Saturday, December 9,
2017Location: Georgia World Congress Center, Hall
A2
Poster, Abstract #4057
Title: Safety and Activity of the Highly
Specific BTK Inhibitor BGB-3111 in Combination with the PD-1
Inhibitor BGB-A317 in Patients with B-Cell Lymphoid
Malignancies
Presenter: Gavin Cull, MD
Session: 623. Mantle Cell, Follicular, and
Other Indolent B-Cell Lymphoma – Clinical Studies: Poster
IIIDate & Time: 6:00pm-8:00pm EST, Monday,
December 11, 2017Location: Georgia World Congress
Center, Hall A2
About BGB-3111
BGB-3111 is a potent and highly selective investigational small
molecule inhibitor of BTK. BGB-3111 has demonstrated higher
selectivity against BTK than ibrutinib, a BTK inhibitor currently
approved by the U.S. Food and Drug Administration and the European
Medicines Agency, based on biochemical assays, higher exposure than
ibrutinib based on their respective Phase 1 experience in separate
studies, and sustained 24-hour BTK occupancy in both the peripheral
blood and lymph node compartments.
About BGB-A317
BGB-A317 is an investigational humanized monoclonal antibody
that belongs to a class of immuno-oncology agents known as immune
checkpoint inhibitors. It is designed to bind to PD-1, a cell
surface receptor that plays an important role in downregulating the
immune system by preventing the activation of T-cells. BGB-A317 has
high affinity and specificity for PD-1. It is differentiated from
the currently approved PD-1 antibodies in an engineered Fc region,
which is believed to minimize potentially negative interactions
with other immune cells. BGB-A317 is being developed as a
monotherapy and in combination with other therapies for the
treatment of a broad array of both solid tumor and hematologic
cancers. BeiGene and Celgene Corporation have a global strategic
collaboration for BGB-A317 for solid tumors.
About BeiGene
BeiGene is a global, commercial-stage, research-based
biotechnology company focused on molecularly targeted and
immuno-oncology cancer therapeutics. With a team of over 700
employees in China, the United States, and Australia, BeiGene is
advancing a pipeline consisting of novel oral small molecules and
monoclonal antibodies for cancer. BeiGene is also working to create
combination solutions aimed to have both a meaningful and lasting
impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle
albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA®
(azacitidine) in China under a license from Celgene
Corporation.i
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the clinical data of BGB-3111 and BGB-A317. Actual results may
differ materially from those indicated in the forward-looking
statements as a result of various important factors, including
BeiGene's ability to demonstrate the efficacy and safety of its
drug candidates; the clinical results for its drug candidates,
which may not support further development; actions of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials; BeiGene's ability to achieve market acceptance in
the medical community necessary for commercial success; BeiGene's
ability to obtain and maintain protection of intellectual property
for its technology and drugs; BeiGene's reliance on third parties
to conduct preclinical studies and clinical trials and
manufacturing; BeiGene’s limited operating history and BeiGene's
ability to obtain additional funding for operations and to complete
the development and commercialization of its drug candidates, as
well as those risks more fully discussed in the section entitled
“Risk Factors” in BeiGene’s most recent quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in BeiGene's subsequent filings with the
U.S. Securities and Exchange Commission. All information in this
press release is as of the date of this press release, and BeiGene
undertakes no duty to update such information unless required by
law.
Investor/Media Contact
Lucy Li, Ph.D.+1 781-801-1800ir@beigene.commedia@beigene.com
_________________________
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of
Celgene Corporation.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2023 to Apr 2024